Video
ACC 2022: Insights from the CoreValve US Pivotal and SURTAVI Trials: Five-Year Incidence, Timing And Predictors of Hemodynamic Valve Deterioration ff Transcatheter snd Surgical Aortic Bioprostheses
05:08
Serge Korjian and Michael Reardon discuss the five-year insights from the CoreValve US Pivotal and SURTAVI Trials presented at ACC 2022.
